In its attempt to “replicate the Gleevec story in other tumor types,” Blueprint Medicines Inc.’s Series B round brought in $25 million that will fund the push led by “an elite group of people who have specialized in developing selective kinase inhibitors to known or very clear genomic drivers of cancers,” said Kyle Kuvalanka, chief business officer.